MediciNova and Zhejiang Medicine to Set Up China JV for Asthma Drug

MediciNova Inc of San Diego has signed a letter of intent with Zhejiang Medicine Co. to set up a joint venture that will develop MediciNova’s asthma drug candidate in China. MN-221 is targeted to treat acute exacerbations of asthma or COPD that do not respond to normal bronchodilator or corticosteroid therapy. Terms of the JV were not disclosed. More details.... Stock Symbols: (NSDQ: MNOV) (JASDQ: 4875)  (SHA: 600216) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});